Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01815749 | Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma | active not recruiting | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT03323151 | A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma(PrE0404) | completed | Phase 1 / Phase 2 | 43 | PrECOG, LLC.OTHER | 1 | Jun 25, 2026 |
| clinicaltrials |
| NCT04257578 | Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 23 | University of WashingtonOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04664179 | EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma(CILESTE) | recruiting | Phase 1 | 52 | Baylor College of MedicineOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06447376 | Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab | recruiting | Phase 1 | 20 | Taylor BrooksOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06785415 | Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 37 | Mayo ClinicOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07150104 | Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 8 | Jun 25, 2026 | clinicaltrials |
| NCT07217119 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 25 | GlaxoSmithKlineINDUSTRY | 8 | Jun 25, 2026 | clinicaltrials |
| NCT07217184 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 30 | GlaxoSmithKlineINDUSTRY | 11 | Jun 25, 2026 | clinicaltrials |
| NCT01657331 | Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)(SGN+Benda) | completed | Phase 1 / Phase 2 | 65 | Columbia UniversityOTHER | 2 | Jun 24, 2026 | clinicaltrials |
| NCT03829540 | CD4CAR for CD4+ Leukemia and Lymphoma | recruiting | Phase 1 | 20 | Huda SalmanOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | recruiting | Phase 1 / Phase 2 | 250 | CellCentric Ltd.INDUSTRY | 5 | Jun 24, 2026 | clinicaltrials |
| NCT03697408 | Itacitinib + Everolimus in Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 23 | University of PennsylvaniaOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03277729 | A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | active not recruiting | Phase 1 / Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04545762 | Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma | recruiting | Phase 1 | 36 | C. Babis AndreadisOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04555551 | MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma | active not recruiting | Phase 1 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05455697 | Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 33 | University of WashingtonOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07658352 | A First-in-Human Study of HP-002 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 114 | Shanghai Helioson Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT00081874 | RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07502768 | Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma(EpiRev-NKT) | recruiting | Phase 1 / Phase 2 | 107 | Rong TaoOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07607925 | A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL | not yet recruiting | Phase 1 / Phase 2 | 49 | GlaxoSmithKlineINDUSTRY | 3 | Jun 18, 2026 | clinicaltrials |
| NCT04906902 | Acalabrutinib in CNSL | active not recruiting | Phase 1 / Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05475925 | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | recruiting | Phase 1 / Phase 2 | 200 | Dren BioINDUSTRY | 9 | Jun 17, 2026 | clinicaltrials |
| NCT05934838 | A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | active not recruiting | Phase 1 | 15 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT01644799 | Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma | completed | Phase 1 | 8 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT01838434 | Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | completed | Phase 1 | 106 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT03602612 | T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05463263 | A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | recruiting | Phase 1 / Phase 2 | 180 | Step Pharma, SASINDUSTRY | 3 | Jun 16, 2026 | clinicaltrials |
| NCT05498545 | Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 8 | Second Affiliated Hospital of Xi'an Jiaotong UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07150091 | Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM | active not recruiting | Phase 1 / Phase 2 | 20 | GlaxoSmithKlineINDUSTRY | 8 | Jun 16, 2026 | clinicaltrials |
| NCT07652138 | Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma | recruiting | Phase 1 | 18 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04483206 | Personalized Autologous Transplant for Multiple Myeloma | recruiting | Phase 1 | 90 | Emory UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04737265 | Pilot Study of an NTproBNP Guided Strategy of Cardioprotection(NTproBNP-Guide) | completed | Phase 1 / Phase 2 | 108 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05414500 | Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides | suspended | Phase 1 | 10 | University of Alabama at BirminghamOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT07612787 | A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma(BELAMI) | not yet recruiting | Phase 1 / Phase 2 | 44 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT01430390 | In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies | active not recruiting | Phase 1 | 19 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03162536 | A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | active not recruiting | Phase 1 / Phase 2 | 190 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03602157 | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | active not recruiting | Phase 1 | 43 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03681561 | Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma | recruiting | Phase 1 / Phase 2 | 54 | Veronika BachanovaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06703892 | A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies(CD20/19 CAR T) | recruiting | Phase 1 | 18 | GenomeFrontier Therapeutics TW Co., Ltd.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07456605 | Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma | recruiting | Phase 1 | 20 | University Health Network, TorontoOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02332850 | Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 83 | Thomas Martin, MDOTHER | 2 | Jun 11, 2026 | clinicaltrials |
| NCT03622788 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT05055063 | A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple Myeloma | recruiting | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07335328 | Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies | not yet recruiting | Phase 1 | 24 | Medical College of WisconsinOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07340853 | CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma | suspended | Phase 1 | 30 | Thomas Martin, MDOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07641010 | PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma | not yet recruiting | Phase 1 / Phase 2 | 112 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT02917083 | CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)(RELY-30) | recruiting | Phase 1 | 60 | Baylor College of MedicineOTHER | 1 | Jun 10, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 25, 2026source: clinicaltrials